LifeMD(US:LFMD)2025-08-05 20:10Financial Performance - Total revenue increased 23% year-over-year to $62.2 million, driven by a 30% increase in telehealth revenue to $48.6 million[7] - Telehealth adjusted EBITDA rose 560% to $3.4 million, while total adjusted EBITDA increased 223% to $7.1 million[6] - Active telehealth subscribers grew 16% year-over-year to approximately 297,000, contributing to a total of 446,411 active subscribers[9] - Total revenues for the first half of 2025 were $127.92 million, up 35% from $94.81 million in the same period of 2024[20] - Consolidated Adjusted EBITDA for the three months ended June 30, 2025, was $7,119,915, significantly higher than $2,203,856 for the same period in 2024[28] - Telehealth Adjusted EBITDA for the three months ended June 30, 2025, reached $3,430,914, compared to $520,010 for the same period in 2024[29] - WorkSimpli Adjusted EBITDA for the three months ended June 30, 2025, was $3,689,001, up from $1,683,845 in the same period of 2024[30] Cash and Debt Management - The company exited the quarter with $36.2 million in cash after paying down $2.1 million of senior debt, fully repaying all remaining senior debt subsequently[6] - The company generated over $8 million in operating cash flow during the quarter[7] - Net cash provided by operating activities for Q2 2025 was $8.64 million, compared to $4.54 million in Q2 2024[22] - Cash at the end of Q2 2025 was $36.23 million, up from $35.70 million at the end of Q2 2024[22] - The company reported a net increase in cash of $1.83 million for Q2 2025, compared to $592,286 in Q2 2024[22] Guidance and Future Outlook - The company revised its full-year 2025 revenue guidance to a range of $250 million to $255 million, down from previous guidance of $268 million to $275 million[11] - The company anticipates strong year-over-year growth in both revenue and adjusted EBITDA despite temporary challenges in the Rex MD business[6] Profitability Metrics - The gross margin was 88%, compared to 90% in the prior-year period, attributed to revenue mix[10] - Operating loss for Q2 2025 was $(906,772), significantly improved from $(6,305,566) in Q2 2024[20] - Net loss attributable to LifeMD, Inc. common stockholders for Q2 2025 was $(2.85) million, compared to $(7.65) million in Q2 2024[20] - Basic loss per share for Q2 2025 was $(0.06), an improvement from $(0.19) in Q2 2024[20] Expenses and Costs - Total expenses for the first half of 2025 were $110.21 million, compared to $97.66 million in the same period of 2024[20] - The company reported interest expense of $562,583 for the three months ended June 30, 2025, compared to $431,024 for the same period in 2024[28] - Total depreciation, amortization, and accretion expense for the three months ended June 30, 2025, was $2,823,100, compared to $2,288,225 for the same period in 2024[28] - The company incurred acquisition expenses of $1,806,277 for the three months ended June 30, 2025, with no such expenses reported in the same period of 2024[29] - Litigation costs for the three months ended June 30, 2025, amounted to $486,462, slightly lower than $495,784 for the same period in 2024[29] - Stock-based compensation expense for the three months ended June 30, 2025, was $2,094,614, compared to $4,191,176 for the same period in 2024[29] - The company reported a foreign exchange loss of $253,512 for the three months ended June 30, 2025, compared to a loss of $504,969 for the same period in 2024[30] Strategic Initiatives - LifeMD launched a nationwide behavioral health offering and acquired a virtual women's health brand to enhance its service offerings[5]